PITTSBURGH, Aug. 26, 2014 /PRNewswire/ -- Intelomed is pleased to announce that Mary Kay Deck (Kay) has joined the team as the Vice President of Clinical Affairs. With over 30 years in clinical, healthcare administration and the medical device industry, Kay's experience in taking medical technology and associated clinical protocols from late stage research and development to global expansion, is a valuable addition to the Intelomed team. "We are very pleased to have Kay on our team, and I am confident her focused and passionate approach will accelerate our efforts to deliver our solutions to multiple clinical care settings," says Frank J. Amoruso, President and CEO of Intelomed. Kay will focus on oversight for the company's clinical activities, use her years of clinical experience to contribute to the design of our solutions, and manage a growing team of sophisticated and impassioned clinicians and researchers. "I believe CVInsight® can be a game-changer. Healthcare needs technology to support patients both within and outside of healthcare facilities. By providing clinicians with the ability to monitor a patient's cardiac stress in a non-invasive, real-time manner, we have the opportunity to make a significant impact on improving patient care, while reducing risks and costs," says Kay.
Intelomed is a privately held medical technology company, established in 2005 and headquartered in Pittsburgh, Pennsylvania. They are focused on developing innovative, non-invasive solutions for monitoring cardiovascular stability in real-time. Intelomed's ability to provide intelligent technology has the potential to directly and positively impact cardiovascular care in multiple patient care settings, initially targeting the hemodialysis, perioperative care and heart failure areas.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage additional sales representatives, the success of such additional sales representatives, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on third party manufacturers to produce our goods on time and to our specifications, and implementation of our sales strategy.